Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Metrics to compare | 6696 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6696PeersSector | |
---|---|---|---|---|
P/E Ratio | −18.0x | −24.7x | −0.5x | |
PEG Ratio | 9.24 | 0.02 | 0.00 | |
Price/Book | 4.7x | 2.8x | 2.6x | |
Price / LTM Sales | - | 30.5x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 43.4% | |
Fair Value Upside | Unlock | −12.7% | 7.1% | Unlock |